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Background: To investigate the obstetrical and perinatal impact of oocyte donation, a cohort of women who
conceived after OD was compared with a matched control group of women who became pregnant through
in vitro fertilisation with autologous oocytes (AO).
Methods: A matched-pair analysis has been performed at the Centre for Reproductive Medicine of the UZ Brussel,
Dutch speaking Free University of Brussel. A total of 410 pregnancies resulted in birth beyond 20 weeks of
gestation occurring over a period of 10 years, including 205 oocyte donation pregnancies and 205 ICSI pregnancies
with autologous oocytes (AO). Patients in the OD group were matched on a one-to-one basis with the AO group
in terms of age, ethnicity, parity and plurality. Matched groups were compared using paired t-tests for continuous
variables and McNemar test for categorical variables. A conditional logistic regression analyses was performed
adjusting for paternal age, age of the oocyte donor, number of embryos transferred, and singleton/twin pregnancy.
Results: Oocyte donation was associated with an increased risk of pregnancy induced hypertension (PIH) (matched
OR: 1.502 CI: 1.024-2.204), and first trimester bleeding (matched OR: 1.493 CI: 1.036-2.15). No differences were
observed between the two matched groups with regard to gestational age, mean birth weight and length, head
circumference and Apgar scores.
Conclusions: Oocyte donation is associated with an increased risk for PIH and first trimester bleeding independent
of the recipients’ age, parity and plurality, and independent of the age of the donor or the partner. However,
oocyte donation has no impact on the overall perinatal outcome.
Keywords: Oocyte donation, Pregnancy outcome, Pregnancy-induced hypertension, First trimester bleedingBackground
Oocyte donation (OD) has been introduced in 1984 to
allow women with ovarian insufficiency to become preg-
nant [1]. The success of the technique led to a broaden-
ing of scope of the treatment to include indications of
repeated IVF failure, advanced maternal age or inherit-
able disease [2]. Today, OD has become well established
with thousands of children born worldwide annually. As
with any other reproductive techniques, assessment of
possible associated obstetric and perinatal risk remains
of paramount importance.
Several authors have reported on the obstetrical and
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reproduction in any medium, provided the orcase reports and series have shown varying results, the
most consistently reported complications are a high inci-
dence of pregnancy induced hypertension (PIH) and first
trimester bleeding [3-7]. Most authors concluded that
pregnancies after oocyte donation need to be considered
as high risk pregnancies, however overall perinatal out-
comes are considered favourable. [5-7].
Pregnancies after oocyte donation represent a unique
group of pregnancies because they are achieved with an
immunologically foreign embryo. This may underlie the
observed increased obstetrical and perinatal risk asso-
ciated with these pregnancies. However, obstetrical risk
factors such as advanced maternal age, primiparity and
multiple pregnancies tend to be more common in this
population. Moreover, there is a higher incidence of po-
tential obstetrical risk factors that necessitate oocytetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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immunologic disorders or severe endometriosis [8-10].
It remains unclear to which extent the increased ob-
stetrical and perinatal risks can be attributed to im-
munological mechanisms or to the aforementioned
confounding risk factors.
We therefore performed a retrospective analysis to in-
vestigate the impact of oocyte donation on the obstetric
and perinatal outcome by comparing with a strictly
matched control group. On a one-to-one basis, the oo-
cyte recipient cohort was matched for age, ethnicity, parity
and plurality, with a cohort of women who underwent in-
vitro fertilisation treatment. Using this methodology we
were able to minimise confounding bias and to investigate




At the Dutch-speaking Brussels Free University, data
collection with regard to the obstetrical and perinatal
outcomes after oocyte donation and after ART have
long been integrated into the clinical programme of
the fertility centre [11]. All pregnancies that occurred
between January 1999 and December 2008, that had
been obtained after oocyte donation and resulted in
offspring after more than 20 weeks of gestation, were
included in this study. Matched controls were selected
from the patient population that underwent in-vitro
fertilisation with autologous oocytes during the same
period. All pregnancies in oocyte recipients and in
controls were conceived after intra cytoplasmic sperm
injection (ICSI). Oocyte recipients underwent embryo
transfer in natural cycles or in artificial cycles supple-
mented with a daily dose of 1600 mg micronised pro-
gesterone and 10 mg oestradiol valerate until 12th
weeks gestation. The individually matched controls
were selected from a total of 3707 ICSI pregnancies
reaching 20 weeks of gestation. Pregnancies after pre-
implantation genetic diagnosis (PGD) or after testicular
sperm extraction (TESE) or use of donor sperm were
not included in this study. The study was approved by
the committe for ethics in medical research of the Free
University of Brussels (12-5-2010; 2010/106; B.U.
N.14320108637).
Data collection
For all pregnancies, written data regarding obstetrical
and neonatal outcome were collected. As a routine pro-
cedure, a questionnaire is send to all patients with an
ongoing pregnancy at seven weeks of gestation and to
their obstetrician around the estimated delivery date. On
average, 95% of the questionnaires are returned, while
another 5% of the patients or their gynaecologists needto be contacted by phone in order to retrieve the out-
come data. Obstetrical complications, perinatal data, in-
cluding gestational age, mode of delivery, birth weight,
Apgar scores, presence or absence of malformations and
neonatal problems were registered. If any problem was
mentioned, detailed information was requested from the
paediatrician in charge.Matching procedure
Matching was performed for maternal age (+/− 12 months),
parity (nulliparity or multiparity), plurality (singleton or
twin) and maternal ethnicity. Matching for the gender of
the child was only performed in singleton pregnancies.
Where multiple matching options existed, case–control
pairs with concordant delivery dates were selected. None
of the oocytes or embryos underwent cryopreservation
prior to embryo transfer.Definitions
Pregnancy-induced hypertension (PIH) was defined as
blood pressure (BP) levels > 140/90 mm Hg on two or
more occasions at least 6 h apart, without proteinuria,
after 20 weeks. Pre-eclampsia: repeated BP levels ≥ 140/
90 mm Hg with proteinuria ≥ 0.3 g/day after 20 weeks
of gestation. Gestational age: calculated from the day of
oocyte aspiration, which was defined as day 14 of the
cycle. Stillbirth: intrauterine or intrapartum death of a
child born with a gestational age ≥ 20 weeks or with a
birth weight of ≥ 500 g. Preterm birth: delivery before
37 completed weeks of gestation. Preterm premature
rupture of the membranes (pPROM) was defined as
rupture of the membranes before 37 weeks of gestation
in the absence of uterine contractions. Perinatal mortal-
ity: number of intrauterine or intrapartum deaths and
neonatal deaths < 7 days after birth per 1000 children
born with a gestational age of ≥ 20 weeks. Low birth
weight: < 2500 g at birth. Very low birth weight: <
1500 g at birth.Statistical analysis
Categorical variables are presented as numerator and
denominator values (%), and continuous variables as
mean (SD, standard deviation) for each group of inter-
est. Paired data from the oocyte donation pregnancies
and their matched controls were analysed using McNe-
mar and paired t-tests for categorical and continuous
variables, respectively. Multivariable modelling was con-
ducted using conditional logistic regression adjusting
for paternal age, age of the oocyte donor, the number
of embryos transferred, and singleton/twin pregnancy.
Pairs with missing outcome data were not included
in our matched analyses. All data were analysed
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Chicago, IL).Results
Characteristics of the oocyte recipients and their matched
controls
Overall, the oocyte donation programme resulted in the
birth of 375 children out of 294 pregnancies (see Add-
itional file 1: Table S1). Among pregnancies that
reached 20 weeks of gestation, 97.9% resulted in a live
birth. The multiple birth rate was 30.3% (89/294).
Singleton pregnancies ended in 2.0% of cases with a
stillbirth, while the stillbirth rate among twin pregnan-
cies was 2.3%. None of the pregnancies was ended by
an elective interruption. Additional file 1: Table S1 lists
further characteristics of this oocyte recipient cohort of
294 OD pregnancies.
An appropriate match was found for 205 OD-
pregnancies resulting in 262 live births. Table 1 lists
characteristics of this oocyte recipient cohort of 205 OD
pregnancies, and their 205 AO individually matched
controls. Although no matching was performed for pa-
ternal age, body mass index (BMI) and smoking be-
haviour, these parameters did not differ between
pregnancies conceived with donated versus those con-
ceived with autologous oocytes. The mean age of the
oocyte donors of 30.7 years was significantly youngerTable 1 Characteristics of the oocyte recipients and their indi
Available data (%) All pregnancies (n = 2
DO AO
Age
Recipient (DO) or ICSI
patient (AO) (%; SD)
410/410 36.0 36.0
(100) (4.5) (4.5)
Donor 406/410 30.7 36.1
(%; SD) (99) (4.4) (4.4)
Partner 400/410 38.1 39.0
(%; SD) (97.5) (6.4) (6.7)
Parity 410/410 0.23 0.23
(%; SD) (100) (0.5) (0.5)
Ethnicity 410/410 202/205 202/205
(% Caucasian mothers) (100) (98.5) (98.5)
Sex baby 524/524 129/262 123/262
(% male) (100) (49.2) (46.9)
BMI 222/410 23.3 23.2
(%; SD) (54.1) (4.4) (3.2)
Smoking 187/410 5/37 6/37
(%; SD) (45.6) (13.5) (16.2)(almost 6 years) than the mean age of the oocyte re-
cipient and their matches.
Obstetrical outcome after oocyte donation versus
autologous matched controls
The incidence of first trimester vaginal bleeding and
pregnancy-induced hypertension was significantly higher
in pregnancies conceived with donated oocytes com-
pared to matched controls with autologous oocytes:
20.6% vs. 10.3% (P value for McNemar test =0.005) and
19.1% vs. 8.3% (P= 0.002), respectively (Table 2). How-
ever, no significant difference was found in singleton
pregnancies with regard to these obstetrical complica-
tions. No difference was observed in the incidence of
nausea or in the incidence of hospital admission for
hyperemesis. Although the observed incidences for com-
plications such as pre-eclampsia (11.8% vs. 6.4%),
HELLP syndrome (0.98% vs. 0.59%) or gestational dia-
betes (7.4% vs. 3.4%) were almost twice as high in preg-
nancies after oocyte donation these differences were not
statistically significantly different.
Infant outcome after oocyte donation versus autologous
matched controls
Gestational age, birth weight, height and head circumfer-
ence and the calculated standard deviations scores were
comparable for both groups (Table 3). The children of
oocyte recipients were not at increased risk for low-vidually matched controls
05) Singletons (n = 148) Twins (n = 57)
P DO AO P DO AO P
0.37 36.3 36.2 0.24 35.4 35.4 0.66
(4.5) (4.5) (4.4) (4.4)
<0.001 31.0 36.3 <0.001 29.8 35.4 <0.001
(4.3) (4.5) (4.6) (4.4)
0.90 38.3 39.1 0.23 37.6 38.9 0.19
(6.2) (6.7) (6.9) (6.5)
0.78 0.2 0.2 0.32 0.2 0.3 0.66
(0.5) (0.5) (0.5) (0.5)
1 146/148 146/148 1 55/57 55/57 1
(98.6) (98.6) (96.5) (96.5)
0.52 66/148 66/148 1 63/114 57/114 0.52
(44.6) (44.6) (55.3) (50.0)
0.92 23.7 23.1 0.35 22.1 23.5 0.14
(4.7) (3.4) (3.4) (3.6)
1 5/31 6/31 1 0 0 1
(16.1) (19.3)
Table 2 Obstetrical outcome in pregnancies with donated oocytes versus individually matched pregnancies with
autologous oocytes
All pregnancies Singletons Twins
DO AO P DO AO P DO AO P
n=205 (%) n = 205 (%) n= 148 (%) n =148 (%) n = 57 (%) n= 57 (%)
Vaginal bleeding
1st trimester 42/204 21/204 0.005 32/148 20/148 0.08 10/57 1/57 0.01
(20.6) (10.3) (21.8) (13.6) (17.5) (1.8)
2nd trimester 5/205 6/204 1 3/148 5/147 0.73 2/57 1/57 1
(2.4) (2.9) (2) (3.4) (3.5) (1.8)
3rd trimester 3/205 3/205 1 2/148 3/148 1 1/57 0/57 1
(1.5) (1.5) (1.4) (2) (1.8) (0)
Nausea and vomiting
1st trim. Nausea 44/205 48/205 0.70 30/148 32/148 0.88 14/57 16/57 0.82
(21.5) (23.4) (20.3) (21.6) (24.6) (28.1)
Hospital admission because of hyperemesis 5/204 0/204 0.06 2/147 0/147 0.50 3/57 0/57 0.25
(2.5) (0) (1.4) (0) (5.3) (0)
Hypertensive disorders
Pregnancy induced hypertension 39/204 17/204 0.002 25/147 13/147 0.05 14/57 4/57 0.02
(19.1) (8.3) (17.0) (8.8) (24.6) (7.0)
Pre-eclampsia 24/204 13/204 0.07 15/147 8/147 0.21 9/57 5/57 0.29
(11.8) (6.4) (10.2) (5.4) (15.8) (8.8)
HELLP syndrome 2/204 1/204 1 1/147 1/147 1 1/57 0/57 1
(1.0) (0.5) (0.7) (0.7) (1.8) (0)
Abnormal Placentation
Placenta praevia 4/204 6/204 0.69 4/147 6/147 0.69 0/57 0/57 1
(2.0) (2.9) (2.7) (4.1) (0) (0)
Placental abruption 0/204 2/204 0.5 0/147 2/147 0.50 0/57 0/57 1
(0) (1.0) (0) (1.4) (0) (0)
Preterm labour
pPROM 7/204 10/204 0.61 2/147 5/147 0.38 5/56 5/56 1
(3.4) (4.9) (1.4) (3.4) (8.9) (8.9)
Preterm labour 32/204 44/204 0.12 15/147 26/147 0.10 17/57 18/57 1
(15.7) (21.6) (10.2) (16.7) (29.8) (31.6)
Gestational diabetes 15/204 7/204 0.10 11/147 4/147 0.07 4/57 3/57 1
(7.4) (3.4) (7.5) (2.7) (7.0) (5.3)
Cholestasis 1/205 2/205 1 0/147 1/147 1 1/57 1/57 1
(0.5) (01.0) (0) (0.7) (1.8) (1.8)
Paired t tests for continuous variables and McNemar test for categorical variables.
DO Donated oocyte; AO Autologous oocyte.
Categorical variables are presented as numerator and denominator values (%), and continuous variables as mean (SD, standard deviation) for each group of
interest.
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poor Apgar scores. A higher incidence of preterm birth
was observed in singletons and twin pregnancies after
oocyte donation: 14.2% vs. 12.2% (P value for McNemar
test <0.001) and 64.9% vs. 57.1% (P value for McNemar
test <0.001), respectively. However, the mean gestationalage, as well as the delivery rate before 34 weeks was not
different.
Mode of delivery
Patients who conceived with donor oocytes were
more likely to deliver by caesarean section (Table 4;
Table 3 Infant outcome in pregnancies with donated oocytes versus individually matched pregnancies with
autologous oocytes
All pregnancies Singletons Twins
DO AO P DO AO P DO AO P
Live births 262 262 148 148 114 114
Gestational age
Mean gestational age 37.29 37.34 0.82 38.72 38.74 0.94 35.40 35.49 0.50
(SD) (3.1) (2.9) (n = 259) (2.3) (2.0) (n = 147) (2.9) (2.8) (n = 112)
< 37 weeks of gestation 95/262 82/259 <0.001 21/148 18/147 <0.001 74/114 64/112 <0.001
(%) (36.3) (31.7) (14.2) (12.2) (64.9) (57.1)
< 34 weeks of gestation 16/237 20/237 0.60 4/145 4/145 1 12/92 16/92 0.54
(%) (6.8) (8.4) (2.8) (2.8) (13.0) (17.4)
Birth weight
Mean birth weight 2832.9 2805.3 0.56 3211.3 3183.4 0.67 2321.2 2294.1 0.70
(SD) (709.9) (711.1) (n = 254) (593.5) (583.4) (n = 146) (504.7) (524.9) (n = 108)
Birth weight 87/256 77/260 0.28 13/147 14/147 0.83 74/109 63/113 0.11
< 2500 g (%) (34) (29.6) (8.8) (9.5) (67.9) (55.8)
Birth weight 7/256 11/260 0.48 3/147 2/147 1 4/109 9/109 0.27
< 1500 g (%) (2.7) (4.2) (2) (1.4) (3.7) (8)
Mean birth length 48.1 48.1 1 49.7 49.6 0.81 45.7 45.8 0.795
(SD) (3.6) (3.5) (n = 233) (2.9) (2.9) (n = 138) (3.2) (3.0) (n = 95)
Mean head circumference 33.6 33.4 0.31 34.2 34.2 0.95 32.7 32.1 0.10
(SD) (2.3) (2.2) (n = 186) (2.2) (2.0) (n = 113) (2.1) (2.0) (n = 73)
APGAR scores
1 minute APGAR scores
Less than 4 3/224 5/233 0.73 2/132 1/133 1.00 1/92 4/100 0.63
(1.3) (2.1) (n = 201) (1.5) (0.8) (n = 120) (1.1) (4.0) (n = 40)
Less than 7 30/224 26/233 0.46 19/132 10/133 0.076 11/92 16/100 0.34
(13.4) (11.2) (n = 201) (14.4) (7.5) (n = 120) (12.0) (16.0) (n = 40)
5 minute APGAR scores
Less than 4 0/224 1/230 1.00 0/132 0/131 NA 0/92 1/99 1.00
(0) (0.4) (n = 201) (0) (0) (0) (1.0) (n = 41)
Less than 7 4/224 4/230 1.00 3/132 1/131 0.63 1/92 3/99 1.00
(1.8) (1.7) (n = 201) (2.3) (0.8) (n = 118) (1.1) (3.0) (n = 41)
10 minute APGAR scores
Less than 4 0/217 0/194 NA 0/131 0/118 NA 0/86 0/76 NA
(0) (0) (0) (0) (0) (0)
Less than 7 0/217 2/194 0.50 0/131 1/118 1.00 0/86 1/75 1.00
(0) (1.0) (n = 163) (0) (0.8) (n = 105) (0) (1.3) (n = 29)
Paired t tests for continuous variables and McNemar test for categorical variables.
DO: Donated oocyte; AO: Autologeous oocyte.
Categorical variables are presented as numerator and denominator values (%), and continuous variables as mean (SD, standard deviation) for each group of
interest.
NA, not applicable.
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68.4%; P = 0.08). The significantly higher incidence of
caesarean sections appears to be associated with a
higher rate of non-elective, rather than electivecaesarean sections. Women pregnant with autologous
oocytes were more likely to undergo induction of
labour and were also more likely to deliver spontan-
eously (Table 4).
Table 4 Induction of labour and mode of delivery
All pregnancies Singletons Twins
DO (%) AO (%) p DO (%) AO (%) P DO (%) AO (%) P
Induction of labour (%) 16/201 (8.0) 41/201 (20.4) <0.001 16/144 (11.1) 36/144 (25.0) 0.004 0/57 (0) 5/57 (8.7) 0.06
Mode of delivery
Spontaneous delivery (%) 53/202 (26.2) 84/202 (41.6) 0.002 46/145 (31.7) 67/145 (46.2) 0.02 7/57 (12.3) 17/57 (29.8) 0.04
Assisted vaginal delivery (%) 30/202 (14.9) 25/202 (12.4) 0.56 28/145 (37.8) 24/145 (26.4) 0.65 2/57 (3.5) 1/57 (1.8) 1
Forceps* (%) 9/30 (30) 5/25 (20) 9/28 (32.1) 4/24 (16.7) 0/2 (0) 1/1 (100)
Ventouse* (%) 21/30 (70) 20/25 (80) 19/28 (67.9) 20/24 (83.3) 2/2 (100) 0/1 (0)
Caesarean section (%) 119/202 (58.9) 93/202 (46.0) 0.01 71/145 (50.0) 54/145 (37.2) 0.06 48/57 (84.2) 39/57 (68.4) 0.08
Elective c. Section (%) 55/119 (46.2) 61/93 (65.6) 31/71 (43.7) 33/54 (61.1) 24/48 (50.0) 28/39 (71.8)
Paired t tests for continuous variables and McNemar test for categorical variables.
DO: Donated oocyte; AO: Autologeous oocyte.
Categorical variables are presented as numerator and denominator values (%), and continuous variables as mean (SD, standard deviation) for each group of
interest.
*Forceps and Ventouse deliveries as proportion of all assisted vaginal deliveries.
** Elective caesarean sections as proportion of all caesarean sections.
Stoop et al. Reproductive Biology and Endocrinology 2012, 10:42 Page 6 of 9
http://www.rbej.com/content/10/1/42Multivariate logistic regression analysis
After testing all the parameters in the multivatiate regres-
sion model, after adjusting for paternal age, donor age,
the number of embryos transferred, and singleton/twin
pregnancy, the only factors that remained statistically sig-
nificant were first trimester vaginal bleeding and PIH,
with matched odds ratios (95% confidence limits) of 1.49
(1.04-2.15) and 1.50 (1.02-2.21), respectively (Table 5).
Discussion
Our analysis provides evidence that oocyte donation is
associated with an increased risk of PIH and firstTable 5 Obstetrical outcome in pregnancies with donated
oocytes versus individually matched pregnancies with
autologous oocytes further adjusted for paternal age,
oocyte age, number of embryos per transfer, and
singleton/twin pregnancy
Obstetrical outcome parameter Matched OR 95% CI
Vaginal bleeding
1st trimester 1.47 1.02 – 2.12
2nd trimester 1.27 0.52 – 3.12
3rd trimester 0.98 0.24 – 3.99
Nausea and vomiting
1st trimester nausea 0.87 0.58 -1.29
Hospital admission because of hyperemesis 1.88 0.59 – 6.04
Hypertensive disorders
Pregnancy induced hypertension 1.50 1.02 – 2.19
Pre-eclampsia 1.31 0.83 – 2.08
Preterm labour
pPROM 0.78 0.29 – 2.13
Preterm labour 0.74 0.47 – 1.16
Gestational diabetes 1.59 0.85 – 2.98trimester vaginal bleeding. Although oocyte donation
cycles appear to be associated with relatively high inci-
dences of preeclampsia, gestational diabetes, preterm
delivery, caesarean section and incidences of labour in-
duction their incidences were not significantly increased
in this study.
To our knowledge this is the largest cohort study
examining the effect of oocyte donation on obstetric and
perinatal outcomes including literally more patients than
all the previous controlled trials cumulatively [12]. Fur-
thermore, this study includes adequate matching for
confounding factors, which was facilitated by a large
prospectively collected ART outcome database. Another
strength of the study is that both cohorts of pregnancies
deriving from donor and autologous oocytes were
matched, not only for age parity and plurality as previ-
ous trials did [12], but also for maternal ethnicity which
may be a factor associated with the incidence of pree-
clampsia [13-15].
Previous studies that compared the obstetrical out-
comes after oocyte donation and after standard in-vitro
fertilisation (IVF) in patients of the same age group
[16,17] have also reported an increased incidence of
PIH. Söderström et al. found a significantly higher inci-
dence of hypertensive disorders in the oocyte recipients
although these individuals also had a significantly higher
incidence of primiparity. Recently, the obstetrical out-
come after oocyte donation compared with a selected
control group, matched for potential confounding para-
meters, was the focus of research in three observational
studies [18-20]. Nevertheless, in all three studies, the
average age of individuals in the control groups was sig-
nificantly lower than the age of the oocyte recipients.
Several trials have shown that the incidence of pree-
clampsia is increased in oocyte recipients; although we
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not significant (p = 0.07). This could be attributed to the
fact that we matched for all potential confounding factor,
including ethnicity. The only study that has similar de-
sign is the trial by Klatsly et al. (2010); nonetheless, our
trial literally outnumbers this trial by 2.5 times including
more than 400 patients in total.
Oocyte donation treatment confers a unique group of
pregnancies partly because this method potentially
extends biological fertility to ages well beyond the aver-
age age of menopause [21,22]. It is therefore important,
but difficult, to identify an adequate control population
without multiple confounding factors. Since nationwide
US epidemiological data suggest that the risk of pre-
eclampsia increases by 30% for every additional year be-
yond the age of 34 [23] we decided to match cases and
controls according to their age. The primary purpose of
the current study was to investigate the effect of dona-
tion; therefore, individual case–control matching also
aimed to control for the confounding effect of parity, as
nulliparity almost triples the risk for pre-eclampsia (2.91,
1.28 to 6.61) [24]. A possible limitation to the present
study is the limited registration of the maternal risk fac-
tors BMI (54.1%) and smoking behaviour (45.6%). How-
ever, the available data showed that the incidence was
similar in the two groups. Because no match was found
for all OD pregnancies in women older than 43 years of
age our comparative analysis do not allow to provide
any statement regarding obstetrical or birth outcomes
for OD pregnancies in this older age group.
Although several authors reported higher incidences
of first trimester bleeding in ART pregnancies as com-
pared to spontaneous pregnancies, it still remained un-
clear whether oocyte donation and the underlying
mechanism leading to first trimester bleeding conferred
two independent risk factors [25]. One study compared
pregnancy outcomes after oocyte donation (n = 51) with
those after IVF pregnancies and observed a significant
increase of first trimester bleeding [17]. However, two
further studies (n = 50; n = 71) did not observe a differ-
ence between these two populations [18,20]. In the
current study (n = 205) we report a significant increase
in first trimester bleeding (OR: 1.49; 95CI 1.036-2.150)
in comparison with a matched control group.
Ongoing spontaneous pregnancies complicated by
first-trimester bleeding confer an increased risk for pre-
term birth and lower birth weight [26,27]. De Sutter
et al. found that the higher incidence of first-trimester
bleeding was also associated with an increased risk for
pregnancy complications in pregnancies following ART
[28]. The study reported a lower mean duration of preg-
nancy and lower birth weight in pregnancies compli-
cated with first trimester vaginal bleeding. However, in
our series, the significant increase in first trimesterbleeding did not negatively affect the perinatal outcome.
The reported higher incidence of first trimester bleeding
in ongoing OD pregnancies may possibly be explained
by a reduced miscarriage vulnerability to first trimester
bleeding. However, this hypothesis cannot be confirmed
by the our data, as the matched controls were selected
from pregnancies reaching 20 weeks of gestation aimed
at evaluating the neonatal outcome.
First-trimester vaginal bleeding may indicate under-
lying placental dysfunction as it is associated with
increased risks of preeclampsia or placental abruption
[27]. Our study did not demonstrate an increased risk
for any of these obstetrical complications in pregnancies
complicated with first trimester bleeding.
As all donated oocytes in our centre undergo fertilisa-
tion by intra cytoplasmic sperm injection (ICSI] we
selected control patients from our ICSI population. A
meta-analysis of eight studies found that the risk for
pre-eclampsia was significantly increased in women
undergoing ART, with odds ratio of 1.55 (95% CI 1.23-
1.95) [29]. Our data show that oocyte donation appears
not to further increase that risk. Four meta-analyses
concluded that compared with spontaneously conceived
singletons, pregnancies after assisted fertilisation are
more likely to be complicated by prematurity or low
birth weight [29-32]. However, a large population-based
cohort study comparing birth weight and gestational age
between siblings born to women who had conceived
both spontaneously and after ART concluded that the
observed increased risks are attributable to the factors
leading to infertility, rather than to the reproductive
technology itself [33].
Conditional logistic regression was performed adjusted
for paternal age, donor age and the number of embryos
transferred. The influence of paternal genes on normal
development and function of the placenta in human is
known [34]. Paternal age is considered as a possible risk
factor because of a potential mechanism leading to pla-
cental dysfunction associated with first trimester bleed-
ing, PIH and preeclampsia [35]. Moreover, there are data
suggesting a link between paternal age and placental
abruption [36]. The mean age of the partner did not dif-
fer between pregnancies with donated versus autologous
oocytes and further statistical analysis did not demon-
strate any correlation between paternal age and adverse
outcome in our series. Although both OD and control
pregnancies were conceived after ICSI fertilisation, the
indication for the ICSI technique differs. The inability to
assess the impact of severe male infertility in the control
population is a limitation to the study as this factor is
known to affect pregnancy outcome.
Hypertensive disorders in pregnancy have a higher in-
cidence in women of advanced age [37,38]. As the ages
of the oocyte donor and the recipient differ significantly
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analysis was further adjusted for age of the oocyte donor
in order to assess its possible influence. The age of the
oocyte did not appear to influence the obstetrical or
perinatal outcome.
Meta-analyses have reported that singleton children
born after ART have an approximately twofold risk of
being born preterm [29-31]. We observe similarly high
incidences of pre-term birth in pregnancies after oocyte
donation and in ICSI pregnancies (14.2% versus 12.2%).
As previously reported, a significantly higher inci-
dence of delivery by caesarean section is observed in
OD pregnancies. The higher incidence of caesarean sec-
tions appears to be associated with a higher proportion
of non-elective, rather than elective caesarean sections.
In spite of a significantly lower incidence of induction
of labour, OD pregnancies are significantly more likely
to end by a non-elective caesarean section. It has been
argued that a higher level of concern underlies the
observed increased incidence of caesarean birth
[4,5,39]. However, ICSI pregnancies with autologous
oocytes have also been associated with a higher level of
concern [40].
Conclusion
In summary, our study demonstrates that oocyte dona-
tion treatment is associated with an increased risk of
first trimester bleeding and pregnancy induced hyperten-
sion in oocyte recipients. A major strength of our ap-
proach is that we largely controlled for known and
important confounding factors. Although the obstetrical
and perinatal outcomes are satisfactory, caution is
mandatory in women with other risk factors undergoing
egg donation.
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